08247 中生北控生物科技
按盘价 
3.700 +0.040 (+1.093%) 盈利能力分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 资产回报率 (%) | -11.564% | -8.174% | -1.997% | 1.339% | -0.185% |
| 股东资金回报率 (%) | -35.517% | -22.492% | -5.597% | 4.244% | -0.645% |
| 资本运用回报率 (%) | -40.359% | -23.055% | -4.803% | 3.154% | -0.521% |
边际利润分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 毛利率 (%) | 38.483% | 41.206% | 44.060% | 39.209% | 41.235% |
| 未计利息、税项、折旧及摊销前利润率 (%) | -23.649% | -12.870% | -1.221% | 11.470% | 12.379% |
| 税前边际利润率 (%) | -36.491% | -22.701% | -6.093% | 4.963% | 1.840% |
| 纯利率 (%) | -27.751% | -16.168% | -4.029% | 2.173% | -0.327% |
变现能力分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 流动比率 (X) | 0.820 X | 0.974 X | 1.092 X | 1.148 X | 1.049 X |
| 速动比率 (X) | 0.665 X | 0.791 X | 0.903 X | 0.988 X | 0.895 X |
财务杠杆分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 总负债 / 总资产比率 (%) | 72.255% | 63.453% | 58.916% | 61.192% | 67.189% |
| 总债项 / 总资产比率 (%) | 40.016% | 32.228% | 26.889% | 25.145% | 28.553% |
| 净债项 / 总资产比率 (%) | 29.326% | 17.938% | 15.631% | 12.323% | 21.236% |
| 总债项 / 股东资金比率 (%) | 135.555% | 91.681% | 71.986% | 73.689% | 98.500% |
| 长期债项 / 股东资金比率 (%) | 8.759% | 4.067% | 2.601% | 7.213% | 5.262% |
| 净债项 / 股东资金比率 (%) | 99.344% | 51.031% | 41.847% | 36.113% | 73.258% |
| 净现金 / (债项) ($) | (1.19亿) | (8.56千万) | (8.80千万) | (7.43千万) | (1.29亿) |
| 每股净现金 / (债项) ($) | (0.825) | (0.592) | (0.608) | (0.514) | (0.892) |
| 总债项 / 资本运用比率 (%) | 128.565% | 83.396% | 62.453% | 59.027% | 79.336% |
| 利息盈利率 (X) | N/A | N/A | N/A | 3.716 X | 1.606 X |
营运效率分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 存货周转率日数 (日) | 156.739日 | 134.715日 | 130.798日 | 92.930日 | 112.040日 |
| 应收贸易帐周转率日数 (日) | 226.006日 | 209.051日 | 249.570日 | 206.902日 | 215.940日 |
| 应付贸易帐周转率日数 (日) | 148.321日 | 137.809日 | 156.919日 | 138.284日 | 141.915日 |
| 备注： | 实时报价更新时间为10/04/2026 17:59 |
| 港股实时基本市场行情由香港交易所提供; 香港交易所指定免费发放实时基本市场行情的网站。 | |
| 股东应占溢利/(亏损) (千) | RMB -51,142 |
| 增长率 | 20.244% |
| 每股盈利/(亏损) | RMB -0.353 |
| 每股账面资产净值 (¥) | RMB 0.831 |